AM-Pharma B.V.: AM-Pharma Provides Business Update and Outcome of Pre-planned Interim Futility Analysis of Phase 3 REVIVAL Study
Phase 3 REVIVAL study stopped per recommendation of data monitoring committee after per-protocol pre-specified interim futility analysis on the study's primary endpoint, 28-day mortality, without